Information on SCN11

Basic details

Name: Severe congenital neutropenia 11 | Acronym: SCN11
Alt. names: Congenital neutropenia, severe, 11

Gene: SEC61A1 | MOI: Autosomal dominant | Mechanism of action: Haploinsufficiency

No. of cases in DB: 1 | First reported in: 2020

Last updated on: 2023-05-26 09:37:54 by Xiao P. Peng

OMIM: 620674

Orphanet: -

MONDO: -

DOID: -

ClinGen:

Description

Thus far, one patient has been reported with a heterozygous SEC61A1 mutation leading to severe congenital neutropenia without hypogammaglobulinemia or nephropathy (PMID: 32325141) - a 19-year-old European female diagnosed with SCN at age 2 years old with a history of recurrent sinopulmonary, GI and skin infections, as well as oral ulcers, defective wound healing, gingivitis, and an episode of limited verrucae plantaris. Immunophenotyping prior to initiation of daily G-CSF was also notable for hypergammaglobulinemia, mild thrombocytopenia, and discrete intermittent anemia. Bone marrow analysis before G-CSF treatment showed granulopoietic maturation arrest at the promyelocyte and myelocyte level, thought to be a consequence of dysregulated unfolded protein response, increased susceptibility to ER stress and greater tendency to apoptosis.

Management

Interestingly, although the patient was clinically responsive to G-CSF, her circulating neutrophils remained immature with evidence of nuclear hypo-segmentation.

1 reported cases added to GenIA

SubjectID Sex Fam.ID AD AFM Validity Country Population Reference & Pub.code
102216arrow icon F 214916tree icon 19 0 Belgium Belgian PMID:32325141 [Patient(II.1)]

AD: Age at genetic diagnosis; AFM: age at first manifestation; PMID: PubMed ID; GRID: GenIA reference ID (ref. not in PubMed).

Summary of clinical findings

[Considering only Definitive and Possible cases]

Rank Clinical term Present Absent Unreported
1 Sinusitisarrow icon 1 (99.9%) 0 (0.0%) 0 (0.0%)
2 Otitis mediaarrow icon 1 (99.9%) 0 (0.0%) 0 (0.0%)
3 Thrombocytopeniaarrow icon 1 (99.9%) 0 (0.0%) 0 (0.0%)
4 (unusual) Respiratory tract infectionarrow icon 1 (99.9%) 0 (0.0%) 0 (0.0%)
5 Septicaemiaarrow icon 1 (99.9%) 0 (0.0%) 0 (0.0%)
6 Increased proportion of plasmablastsarrow icon 1 (99.9%) 0 (0.0%) 0 (0.0%)
7 (Unusual) bacterial infectionarrow icon 1 (99.9%) 0 (0.0%) 0 (0.0%)
8 Wartsarrow icon 1 (99.9%) 0 (0.0%) 0 (0.0%)
9 Neutropeniaarrow icon 1 (99.9%) 0 (0.0%) 0 (0.0%)
10 Lung diseasearrow icon 1 (99.9%) 0 (0.0%) 0 (0.0%)
11 Anemiaarrow icon 1 (99.9%) 0 (0.0%) 0 (0.0%)
12 Hyperuricemiaarrow icon 1 (99.9%) 0 (0.0%) 0 (0.0%)
13 Hypergammaglobulinaemiaarrow icon 1 (99.9%) 0 (0.0%) 0 (0.0%)
14 (unusual) Viral infectionarrow icon 1 (99.9%) 0 (0.0%) 0 (0.0%)
15 Pleural empyemaarrow icon 1 (99.9%) 0 (0.0%) 0 (0.0%)
16 Tonsillitisarrow icon 1 (99.9%) 0 (0.0%) 0 (0.0%)
17 Bronchitisarrow icon 1 (99.9%) 0 (0.0%) 0 (0.0%)
18 Perianal Abscessarrow icon 1 (99.9%) 0 (0.0%) 0 (0.0%)
19 Cutaneous abscessarrow icon 1 (99.9%) 0 (0.0%) 0 (0.0%)
20 Pneumoniaarrow icon 1 (99.9%) 0 (0.0%) 0 (0.0%)
21 Aphthous oral ulcerarrow icon 1 (99.9%) 0 (0.0%) 0 (0.0%)
22 Gingivitisarrow icon 1 (99.9%) 0 (0.0%) 0 (0.0%)
23 Skin infections arrow icon 1 (99.9%) 0 (0.0%) 0 (0.0%)
24 Chronic kidney diseasearrow icon 0 (0.0%) 1 (99.9%) 0 (0.0%)

Summary of treatment outcomes

[Considering only Definitive and Possible cases]

Treatment ⓘ Responses & clinical indications